Inhibition of Choroidal Neovascularization via Brief Subretinal Exposure to a Newly Developed Lentiviral Vector Pseudotyped with Sendai Viral Envelope Proteins
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Lentiviral vectors are promising tools for the treatment of chronic retinal diseases, including age-related macular degeneration (AMD), as they enable stable transgene expression. On the other hand, Sendai virus (SeV) vectors provide the unique advantage of rapid gene transfer. Here we show that novel simian immunodeficiency viral vectors pseudotyped with SeV envelope proteins (SeV-F/HN-SIV) achieved rapid, efficient, and long-lasting gene transfer in the mouse retina. Subretinal exposure to SeV-F/HN-SIV vectors for only a few minutes resulted in high-level gene transfer to the retinal pigment epithelium, whereas several hours were required for gene transfer by standard vesicular stomatitis virus G-pseudotyped SIV vectors. Transgene expression continued over a 1-year period. SeV-F/HN-SIV vector-mediated retinal overexpression of soluble Fms-like tyrosine kinase-1 (sFlt-1) or pigment epithelium-derived factor (PEDF) significantly suppressed laser-induced choroidal neovascularization (CNV). Histologically, 6-month-long sustained overexpression of PEDF did not adversely affect the retina; however, that with sFlt-1 resulted in photoreceptor degeneration associated with choroidal circulation defects. These data demonstrate that brief subretinal administration of SeV-F/HN-SIV vectors may facilitate safe and efficient retinal gene transfer, and suggest the therapeutic potential of PEDF with a higher safety profile for treating CNV in AMD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 4×
“Clinical data analyses have revealed that the intravitreal administration of VEGF-A antagonists such as ranibizumab, bevacizumab, and pegaptanib arrests CNV progression and leakage from CNV, and improves visual acuity (Gragoudas et al., 2004; Avery et al., 2006; Brown et al., 2006; Rosenfeld et al., 2006).”
InfluentialPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 2×
“…the beneficial therapeutic effects of intravitreal injection of anti-VEGF-A drugs such as pegaptanib (an aptamer specific for VEGF-A 165 ) and ranibizumab (an Fab fragment of a humanized monoclonal pan-VEGF-A antibody) (Gragoudas et al. , 2004; Brown et al. , 2006; Rosenfeld et al. , 2006).”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“…and efficacy of the subretinal delivery of rAAV carrying the RPE65 gene for patients with Leber’s congenital amaurosis, thereby providing the proof of concept for retinal gene therapy strategies (Bainbridge et al. , 2008; Hauswirth et al. , 2008; Maguire et al. , 2008; Cideciyan et al. , 2009).”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×
“The clinical study has shown that the viral vector solution left in the subretinal space is almost fully absorbed by 24hr after injection (Bainbridge et al. , 2008); however, it is more preferable to remove the vector solution and resolve the retinal detachment (RD) during gene transfer surgery,…”
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“…and lentiviral vectors are likely to be useful for patients with chronic progressive retinal diseases, as these vectors can achieve gene transfer in nondividing cells and yield long-term transgene expression (Miyoshi et al. , 1997; Acland et al. , 2001; Lai et al. , 2002; Ikeda et al. , 2003).”
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Friedman, D. S. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.7.1019 · Cited by 656
Tsutsumi, C., Sonoda, K.-H., Egashira, K., Qiao, H., Hisatomi, T., Nakao, S., Ishibashi, M., Charo, I. F., Sakamoto, T., Murata, T., et al. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0902436 · Cited by 277 · cited 1×
“Laser photocoagulation (630nm, 150mW, 0.1sec, 75 m m) was performed on one eye (four spots per eye) of each animal, using a slit-lamp delivery system (NIDEK, Aichi, Japan), as previously described (Tsutsumi et al. , 2003).”
Self-citationEfficient gene transfer to airway epithelium using recombinant Sendai virus
Yonemitsu, Y., Kitson, C., Ferrari, S., Farley, R., Griesenbach, U., Judd, D., Steel, R., Scheid, P., Zhu, J., Jeffery, P. K., et al. (2000) · Nature Biotechnology · doi:10.1038/79463 · Cited by 244 · cited 1×
“The F and HN proteins of SeV mediate viral attachment and penetration (Lamb and Kolakofsky, 1996), and SeV-derived vectors have shown efficient gene transfer with only a few minutes of vector–cell interaction (Yonemitsu et al. , 2000; Masaki et al. , 2001).”
Jacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224 · cited 1×
“Although subretinal injection of rAAV-RPE65 at the doses used in clinical studies has been shown to be safe in dogs and nonhuman primates (Jacobson et al. , 2006a,b), retinal thinning was observed after subretinal injection of rAAV-RPE65 in one of three patients (Hauswirth et al. , 2008).”
Cited by
Mechanisms of Age-Related Macular Degeneration
Ambati, J., & Fowler, B. J. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.018 · Cited by 1,021
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Cuenca, N., Fernández-Sánchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., & Pinilla, I. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.07.001 · Cited by 401
Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases
Peng, Y., Tang, L., & Zhou, Y. (2017) · Ophthalmic Research · doi:10.1159/000479157 · Cited by 175
Lentiviral vectors for ocular gene therapy
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081605 · Cited by 47
“(2010) pseudotyped SIV vectors with a Sendai envelope (SeV-SIV) to optimize gene expression before testing them in two different approaches of gene transfer in the RPE cells to suppress laser photocoagulation-induced CNV [109].”
BackgroundMethodInfluential
Metadata
- Authors
- Murakami, Y., Ikeda, Y., Yonemitsu, Y., Miyazaki, M., Inoue, M., Hasegawa, M., Sueishi, K., & Ishibashi, T.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2010-02
- Volume
- 21
- Issue
- 2
- Pages
- 199-209
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2090197687
- Cited by
- 40
- References
- 12
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.